New drug valbenazine tested for Huntington's movement problems
NCT ID NCT06312189
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at the long-term safety of valbenazine for people with Huntington disease who have involuntary jerking movements (chorea). It includes 7 participants from Canada who were in a previous valbenazine study. Everyone gets the drug, and researchers track side effects over time.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- valbenazine
- What this could lead to
- If successful, this could confirm valbenazine as a safe long-term option to reduce involuntary movements in Huntington disease.
- What could go wrong
- This is a very small open-label study with only 7 participants, no placebo group, and focuses on safety rather than effectiveness. Results may not apply broadly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
About 7 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2024
- Expected to finish
-
Apr 2028
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Key Inclusion Criteria: * Participated in Study NBI-98854-HD3006 and completing dosing through the Week 156 visit; or were actively participating, receiving study treatment, and completed an early termination visit Study NBI-98854-HD3006 at the time of the study closure at sites in Canada. * Participants of childbearing potential must agree to use contraception consistently while participating in the study until 30 days after last dose of the study treatment. Key Exclusion Criteria: * Have difficulty swallowing * Are currently pregnant or breastfeeding * Have a medically significant abnormality, physical examination finding, clinically significant laboratory abnormality
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chorea, Huntington are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
3 sites. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Neurocrine Clinical Site
Vancouver, British Columbia, V6T 2B5, Canada
-
Neurocrine Clinical Site
Ottawa, Ontario, K1Y 4E9, Canada
-
Neurocrine Clinical Site
Toronto, Ontario, MK2 1E1, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.